Cohorte Constances - INSERM UMS 11 – Unité Cohortes épidémiologiques en population

What Cohorte Constances - INSERM UMS 11 – Unité Cohortes épidémiologiques en population does

Cohorte Constances is a large-scale, population-based epidemiological research cohort operated as INSERM UMS 11 (Unité Cohortes épidémiologiques en population), a unit of the French public research institute INSERM and headquartered in Villejuif, France. Between 2012 and 2020 the cohort enrolled approximately 220,000 volunteers aged 18–69 affiliated with the French social security system in selected departments, with an additional ~435,000 reference cohort members followed passively through administrative databases. Its core product is the Constances Cohort Platform, which collects questionnaire data, in-person health examination data, biological samples (biobank), and links to national administrative systems (SNDS, CNAV), enriched with occupational and residential environmental exposure matrices. Supporting applications include AQUEDUC (questionnaire metadata documentation), STETHOSCOPA (descriptive statistics exploration), and secure data access through CASD.

Constances is funded as a public research infrastructure rather than a commercial enterprise: baseline financing comes from French state sources (ANR, France 2030, INSERM, CNAM, l'Assurance Retraite), with private industry co-funding channeled through Inserm Transfert via multiproject and project partnerships with pharmaceutical and consumer-health firms (MSD France, Lilly France, AstraZeneca France, Quinten Health, Bruker, Incyte France, L'Oréal, Astellas, Lundbeck). Data access is governed by an International Scientific and Ethical Committee under CNIL/GDPR compliance, and is delivered exclusively through the secure CASD environment. Marie Zins serves as the publication director and scientific/technical lead. The asset is a research platform serving the academic and public-health research community as its primary user base, with pharmaceutical and consumer-health partners as a secondary, fee-paying segment.

Name

Cohorte Constances - INSERM UMS 11 – Unité Cohortes épidémiologiques en population

Legal name

Institut national de la santé et de la recherche médicale (Inserm)

Website

https://constances.fr

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Cohorte Constances (INSERM UMS 11) operates a French population-based epidemiological cohort of 220,000 volunteers, providing linked questionnaire, health exam, biobank, and administrative data to academic researchers and private health-industry partners through secure, ethically governed access.

Ownership category

akta.pro rank

Product category

Population Health Research Infrastructure

NAICS

Health Care and Social Assistance (62)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM)

akta.pro secondary industries

Population Health Surveillance & Epidemiologic Analytics (HLAJAJAB), Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS) (HLAJABAN), Social Determinants of Health (SDOH) & Equity Measurement (HLAJAJAI), Healthcare Utilization, Claims & Administrative Data Analytics (HLAJAJAK)

Keywords

• Population health research
• Epidemiological cohort study
• Longitudinal health data
• Real-world evidence generation
• Public health biobank

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others

Distribution channels3 records

Marketing channels2 records

Core offering

Constances operates a large-scale population-based epidemiological cohort of 220,000 adult volunteers aged 18-69 followed since 2012, collecting longitudinal health, socioeconomic, occupational, environmental and lifestyle data through questionnaires, in-person health examinations, and linkage to French administrative health and retirement databases (SNDS, CNAV). It offers researchers access to this multi-source data, a linked biobank, validated diagnostic adjudication, and environmental/occupational exposure matrices, with data delivery handled through the secure CASD platform. The cohort also serves as a real-world evidence platform for public-private research partnerships coordinated by Inserm Transfert.

Product overview

Constances is a large-scale population-based epidemiological cohort study comprising approximately 220,000 volunteers enrolled since 2012, designed to describe and track health status, morbidity, mortality, socioeconomic factors, professional status, environmental exposures, and personal risk factors over time. The offering consists of the core cohort platform with its associated data collection infrastructure, supplemented by specialized applications: AQUEDUC for questionnaire documentation and metadata management, STETHOSCOPA for statistical analytics, and a biobank for biological samples. Data access for authorized researchers is provided exclusively through the secure CASD (Centre d'Accès Sécurisé aux Données) platform, which delivers Constances data linked to the French National Health Data System (SNDS).

Differentiator

Problem solved

Functional benefit

Brands

• AQUEDUC: Application dedicated to documentation of cleaning/recoding procedures and constructed variables from questionnaire data
• STETHOSCOPA
• SAPRIS

Products and services

• Constances Cohort Platform Large-scale population-based epidemiological cohort study comprising 220,000 volunteers aged 18-69 followed since 2012, collecting health status, morbidity, mortality, socioeconomic and professional status, family/social environment, residential environment, and personal/environmental risk factors, made available to authorized scientific and industry researchers.
• AQUEDUC Application DDI-compliant application that documents the cleaning, recoding procedures, and constructed variables applied to Constances questionnaire data, providing researchers with metadata on survey variables, statistics, and data cleaning methodologies.
• STETHOSCOPA Application Data exploration tool providing researchers with rapid access to detailed descriptive statistics of inclusion and follow-up survey data, including self-questionnaire data, CNAV unemployment data, SNDS healthcare consumption data, and algorithmically derived diagnoses.
• Constances Biobank Biological sample repository (sera, plasma, DNA, urine) collected from cohort participants, stored and made accessible to authorized researchers in conjunction with the Constances cohort data.
• CASD Secure Data Access Service Secure data delivery service providing authorized researchers with Constances data linked to the French National Health Data System (SNDS), accessed within a protected environment managed by the Centre d'Accès Sécurisé aux Données (CASD).

Quantifiable outcome

• 220,000 volunteers recruited and followed
• +4 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Partnerships

Ten partnerships are on record, tiered core, major and standard.

• Inserm TransfertcoreStrategic or Co-development PartnerInserm Transfert is the private subsidiary of Inserm that manages economic valorization and knowledge transfer from Inserm research laboratories to industry. Inserm Transfert has been supporting the Constances cohort since 2012 in establishing public-private partnerships with health sector industrials.
• MSD FrancemajorStrategic or Co-development PartnerMultiproject partnership from 2014-2027. MSD France supports the cohort and accesses research capabilities through this long-term partnership.
• Quinten HealthmajorStrategic or Co-development PartnerMultiproject partnership from 2024-2028. Partnership for research collaboration with data analytics expertise.
• Lilly FrancemajorStrategic or Co-development PartnerMultiproject partnership from 2023-2026. Partnership for pharmaceutical research using cohort data.
• BrukerstandardStrategic or Co-development PartnerProject partnership from 2023-2025. Technology partnership for medical/scientific equipment.
• Incyte FrancestandardStrategic or Co-development PartnerProject partnership from 2022-2023. Onco-immunology research partnership.
• L'OréalstandardStrategic or Co-development PartnerProject partnership from 2018-2023. Research partnership in occupational and environmental health.
• AstellasstandardStrategic or Co-development PartnerProject partnership from 2014-2020. Pharmaceutical research collaboration.
• AstraZeneca FrancestandardStrategic or Co-development PartnerProject partnership from 2022. Pharmaceutical research partnership.
• LundbeckstandardStrategic or Co-development PartnerProject partnership from 2014-2020. Neuroscience research partnership.

Recent moves6 records

Expansion highlights4 records

Direct peers

• Million Veteran Program (US Department of Veterans Affairs): US veteran population cohort targeting 1 million+ participants with deep genomic, phenotypic, and VA health record data. Comparable in being a large public-sector longitudinal cohort with controlled researcher access and biobanking infrastructure.
• Danish National Birth Cohort: Nationwide Danish cohort of ~100,000 pregnancies with long-term follow-up of mothers and children, including biosamples and registry linkage. Comparable in Nordic/European public cohort design, biobank integration, and registry linkage architecture.
• HUNT (Trøndelag Health Study, Norway): Norwegian population-based cohort with ~230,000 participants across multiple waves, including biospecimens and linkage to national health registries. Comparable in scale, longitudinal design, and public/non-profit operating model with researcher-mediated access.
• EPIC (European Prospective Investigation into Cancer and Nutrition): Multi-country European prospective cohort coordinated by IARC with ~520,000 participants across ten countries, collecting diet, lifestyle, biological samples, and cancer incidence data. Highly comparable in mission (population health epidemiology), data depth (questionnaire + biobank), and multi-source data integration.
• ALSPAC (Avon Longitudinal Study of Parents and Children): UK birth cohort with multi-generational follow-up, rich phenotypic and biosample data, and controlled data access. Comparable in longitudinal design, biobank-linked data, and academic/governance-controlled access model.
• KORA (Cooperative Health Research in the Region Augsburg, Germany): Population-based German cohort operated by Helmholtz Munich with multiple survey waves, biobanking, and focus on cardiovascular, metabolic, and environmental health. Comparable in research mission, multi-wave longitudinal design, and public research institute governance.
• UK Biobank: Large-scale UK population-based prospective cohort with ~500,000 participants, extensive phenotypic and genomic data, biobank, and linkage to NHS health records. Operates as a non-profit resource with fee-based access for academic and commercial researchers — the most direct structural analog to Constances in scale and access model.
• All of Us Research Program (NIH): US NIH-funded longitudinal cohort targeting 1 million+ participants with deep phenotypic data, electronic health record linkage, and biobank. Comparable in being a publicly funded population cohort with controlled researcher access, though at materially larger scale and with US federal funding dynamics.
• Generation Scotland: Scottish family-based population cohort with ~24,000 participants, extensive genomic and phenotypic data, and linkage to NHS health records. Comparable in public-sector research cohort design with controlled academic and industry access pathways.
• LifeLines (Netherlands): Dutch multi-generational population cohort with ~167,000 participants, deep phenotypic data, biobank, and linkage to national health registries. Comparable in scope, governance model (controlled researcher access), and European public-health research mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inserm-ums-11-%E2%80%93-unit%C3%A9-cohortes-%C3%A9pid%C3%A9miologiques-en-population-constances-gazel

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cohorte Constances - INSERM UMS 11 – Unité Cohortes épidémiologiques en population